S. aureus is an opportunistic bacterial pathogen with the potential to cause a range of serious life-threatening diseases (such as pneumonia, bacteremia, osteomyelitis, endocarditis, and sepsis) and pose a public health burden. S. aureus is the leading cause of infection in hospitalized patients, accounting for 20% to 25% of all hospital infections. Staphylococcal infections occur most commonly when the skin or mucosal barrier is disrupted, after insertion of a foreign body, and in hosts with a compromised immune system.
Currently, it has been well documented that the ability of S. aureus to acquire antibiotic resistance and adapt to new antibiotics, makes S. aureus control increasingly difficult. There is an urgent need to develop protective infections against S. aureus. The success of polysaccharide-based vaccines against pathogens such as Haemophilus influenzae has saved millions of lives, and scientists have also worked hard to develop surface polysaccharide vaccines based on S. aureus.
Fig.1 Selected S. aureus virulence factors. (Daum & Spellberg, 2012)
S. aureus Polysaccharide Antigen Production Service at CD BioGlyco
As a state-of-the-art Glyco™ Vaccine Development company, CD BioGlyco provides clients with Polysaccharide Antigen Production Services against various pathogens. It is found that capsular polysaccharide (CP) on the surface of most clinical S. aureus isolates, especially CP conjugated to the carrier protein, could be an effective vaccine antigen. Although 13 putative S. aureus CP have been reported, only serotypes 5 (CP5) and 8 (CP8) have been associated with the disease. They are composed of repeating units of N-acetyl mannosaminuronic acid (ManNAc), N-acetyl-l-fucosamine (l-FucNAc), and N-acetyl-d-fucosamine (d-FucNAc).
To effectively improve the immunogenicity of bacterial polysaccharides and induce T cell-dependent immune responses, we provide clients with high-quality CP5 and CP8 conjugation services on the surface of S. aureus with various carrier proteins such as Pseudomonas aeruginosa exotoxin A (PEA), cross-reacting material 197 (CRM197), human serum albumin (HSA). We use a modified ethanol precipitation method to extract polysaccharides from S. aureus strains and perform ion-exchange purification of the polysaccharide grades by chromatographic columns to obtain pure target polysaccharides. Conjugates of CP5 or CP8 and carrier proteins are obtained using appropriate Conjugation Techniques and analyzed by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blot (WB) analysis.
Fig.2 Flowchart of polysaccharide antigen production. (CD BioGlyco)
With extensive experience and technical experts in the field of Polysaccharide Vaccine Development, CD BioGlyco is capable of providing high-quality polysaccharide antigen production services. Our technical team is proficient at applying various advanced technologies to deal with different situations. If you are interested in our services, please feel free to contact us.
References:
